Fig. 1. Investigator-assessed progression-free survival (A) overall, (B) by del(17)(p13.1) and/or mutated TP53 status, and (C) by IGHV mutation status.

^aHazard ratio was based on stratified Cox-Proportional-Hazards model; ^bP value was based on stratified log-rank test; ^cHazard ratio was based on unstratified Cox-Proportional-Hazards model. ^dP value was based on unstratified log-rank test. A acalabrutinib, CI confidence interval, Clb chlorambucil, HR hazard ratio, IGHV immunoglobulin heavy chain variable region, mTP53 mutated TP53, NR not reached, O obinutuzumab, PFS progression-free survival, w/o without.